Cargando…

Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α

BACKGROUND: Tumor cells have evolved complex strategies to escape immune surveillance, a process which involves NK cells and T lymphocytes, and various immunological factors. Indeed, tumor cells recruit immunosuppressive cells [including regulatory T-cells (Treg), myeloid-derived suppressor cells (M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alves, Raquel, McArdle, Stephanie E. B., Vadakekolathu, Jayakumar, Gonçalves, Ana Cristina, Freitas-Tavares, Paulo, Pereira, Amélia, Almeida, Antonio M., Sarmento-Ribeiro, Ana Bela, Rutella, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941328/ https://www.ncbi.nlm.nih.gov/pubmed/31900171 http://dx.doi.org/10.1186/s12967-019-02194-x

Ejemplares similares

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
por: Alves, Raquel, et al.
Publicado: (2021)

T-Cell Manipulation Strategies to Prevent Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation
por: Vadakekolathu, Jayakumar, et al.
Publicado: (2017)

Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis
por: Alves, Raquel, et al.
Publicado: (2022)

Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia
por: Alves, Raquel, et al.
Publicado: (2022)

S129: ADOPTIVELY INFUSED MEMORY-LIKE (ML) NATURAL KILLER (NK) CELLS ELICIT ADAPTIVE IMMUNE RESPONSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
por: Rutella, Sergio, et al.
Publicado: (2023)

P659: BUPARLISIB A PROMISING THERAPEUTIC APPROACH IN CHRONIC MYELOID LEUKEMIA RESISTANT TO IMATINIB
por: Alves, Raquel, et al.
Publicado: (2023)

Zinc Prevents DNA Damage in Normal Cells but Shows Genotoxic and Cytotoxic Effects in Acute Myeloid Leukemia Cells
por: Costa, Maria Inês, et al.
Publicado: (2022)

Alvespimycin Inhibits Heat Shock Protein 90 and Overcomes Imatinib Resistance in Chronic Myeloid Leukemia Cell Lines
por: Alves, Raquel, et al.
Publicado: (2023)

Hyperactive neutrophil chemotaxis contributes to anti‐tumor necrosis factor‐α treatment resistance in inflammatory bowel disease
por: Yau, Tung On, et al.
Publicado: (2022)

Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer
por: Foulds, Gemma A., et al.
Publicado: (2018)

MicroRNA signature refine response prediction in CML
por: Alves, Raquel, et al.
Publicado: (2019)

A Novel HAGE/WT1-ImmunoBody(®) Vaccine Combination Enhances Anti-Tumour Responses When Compared to Either Vaccine Alone
por: Almshayakhchi, Rukaia, et al.
Publicado: (2021)

AZD-7648, a DNA-PK Inhibitor, Induces DNA Damage, Apoptosis, and Cell Cycle Arrest in Chronic and Acute Myeloid Leukemia Cells
por: Lapa, Beatriz Santos, et al.
Publicado: (2023)

Antitumor Effect of Brusatol in Acute Lymphoblastic Leukemia Models Is Triggered by Reactive Oxygen Species Accumulation
por: Jorge, Joana, et al.
Publicado: (2022)

Parthenolide Induces ROS-Mediated Apoptosis in Lymphoid Malignancies
por: Jorge, Joana, et al.
Publicado: (2023)

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia
por: Ragaini, Simone, et al.
Publicado: (2022)

Zinc: From Biological Functions to Therapeutic Potential
por: Costa, Maria Inês, et al.
Publicado: (2023)

A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8(+) T Cells with Ex Vivo Cytotoxic Capacities in HHDII/DR1 Transgenic Mice
por: Vu, Pauline Le, et al.
Publicado: (2022)

PB1822: INHIBITION OF THE DNA DAMAGE RESPONSE: A POSSIBLE NEW ROUTE IN ACUTE MYELOBLASTIC LEUKEMIA TREATMENT
por: Lapa, Beatriz, et al.
Publicado: (2023)

Multi-Omic Analysis of Two Common P53 Mutations: Proteins Regulated by Mutated P53 as Potential Targets for Immunotherapy
por: Vadakekolathu, Jayakumar, et al.
Publicado: (2022)

Canonical and truncated transglutaminase-2 regulate mucin-1 expression and androgen independency in prostate cancer cell lines
por: Atobatele, Adeola Grace, et al.
Publicado: (2023)

Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
por: Rychter, Anna, et al.
Publicado: (2017)

PB1719: NIRAPARIB IN B-CELL LYMPHOID MALIGNANCIES: EXPLORING SYNTHETIC LETHALITY AS TARGET FOR THERAPY
por: Lapa, Beatriz, et al.
Publicado: (2023)

Platelet Membrane Proteins as Pain Biomarkers in Patients with Severe Dementia
por: Ribeiro, Hugo, et al.
Publicado: (2023)

Monocytes in the Characterization of Pain in Palliative Patients with Severe Dementia—A Pilot Study
por: Ribeiro, Hugo, et al.
Publicado: (2023)

DNA Methylation Is Correlated with Oxidative Stress in Myelodysplastic Syndrome—Relevance as Complementary Prognostic Biomarkers
por: Gonçalves, Ana Cristina, et al.
Publicado: (2021)

P841: MOLECULAR MECHANISMS OF RESISTANCE TO IMMUNOMODULATORS IN MULTIPLE MYELOMA: AN IN VITRO STUDY
por: Alves, Raquel, et al.
Publicado: (2023)

Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors
por: Rodrigues-Santos, Paulo, et al.
Publicado: (2018)

PB1908: NRF2 INHIBITION IN COMBINATION WITH IBRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA– AN IN VITRO STUDY
por: Jorge, Joana, et al.
Publicado: (2023)

PB1910: TELAGLENASTAT (CB-839) IN MONOTHERAPY AND IN COMBINATION WITH EPIGENETIC MODULATORS OR IBRUTINIB INDUCES CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
por: Jorge, Joana, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Performance of spectral flow cytometry and mass cytometry for the study of innate myeloid cell populations
por: van der Pan, Kyra, et al.
Publicado: (2023)

Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia
por: Rutella, Sergio, et al.
Publicado: (2022)

NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors
por: Almeida, Jani-Sofia, et al.
Publicado: (2019)

Gene Expression Profiling of FFPE Samples: A Titration Test
por: Manjunath, Harshitha Shobha, et al.
Publicado: (2022)

Outcome of 3 pregnancies in a patient with chronic myeloid leukemia who received 3 types of tyrosine kinase inhibitors each in different pregnancy: follow-up of the case with a review of published reports
por: Alizadeh, Hussain, et al.
Publicado: (2015)

Analysis of Myeloid Cells in Mouse Tissues with Flow Cytometry
por: Liu, Zhaoyuan, et al.
Publicado: (2020)

Calibration-Aimed Comparison of Image-Cytometry- and Flow-Cytometry-Based Approaches of Ploidy Analysis
por: Jónás, Viktor Zoltán, et al.
Publicado: (2022)

Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring
por: Martins, Ivana, et al.
Publicado: (2021)

Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors
por: Jun, Kong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kbcs243lvti29k5eu9kbihl4ij